Overview
Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis
Status:
Recruiting
Recruiting
Trial end date:
2021-12-31
2021-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim of this study is to determine whether oral Chinese herbal medicine in combination secukinumab is effective and safe in the treatment of severe psoriasis.Phase:
Early Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Guangdong Provincial Hospital of Traditional Chinese MedicineTreatments:
Antibodies, Monoclonal
Criteria
Inclusion Criteria:1. Psoriasis Area and Severity Index (PASI) scoreā„10
2. Meet the requirement of using secukinumab; without the history of inflammatory bowel
disease (IBD)
3. Written/signed informed consent
Exclusion Criteria:
1. Unsuitable for the treatment of secukinumab